A disruptive technology that saves lives and improves patient care Main menu Marx Biotechnology is developing a proprietary first-in-class molecular diagnostic kit for the early detection of Graft versus Host Disease (GVHD). GVHD is a life threatening complication of allogeneic (non-self) stem cell transplantation such as bone marrow, peripheral blood or cord blood transplantation <\/p>\n
and solid organ transplantations. The cells from the donor react <\/p>\n
adversely to the cells in the patient. GVHD affects approximately 50% of all such transplant patients, frequently resulting in death. https:\/\/www.youtube.com\/watch?v=c_8PcfZSkrI<\/a> Marx Bios approach has 5 clear advantages: <\/p>\n Incorporated in Jerusalem in January 2011, the Marx Bio team has completed proof of concept in animal studies, has published in a peer reviewed journal, and has filed three patents. It is commencing a Phase 1 clinical trial in humans in Tel Aviv. <\/p>\n Marx Bio has a clear work schedule to deliver a validated and cleared product, ready for market entry within 36 to 48 months. The company is looking for strategic partners to join in that journey. <\/p>\n <\/p>\n See the article here: A disruptive technology that saves lives and improves patient care Main menu Marx Biotechnology is developing a proprietary first-in-class molecular diagnostic kit for the early detection of Graft versus Host Disease (GVHD). GVHD is a life threatening complication of allogeneic (non-self) stem cell transplantation such as bone marrow, peripheral blood or cord blood transplantation and solid organ transplantations. Continue reading
\nMarx Biotechnology A disruptive technology that saves ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"